CNMP EGFR mutado. A favor de no hacer secuenciación

Front-line EGFR TKI vs. EGFR TKI

Trial

TKI

Comparator

N mPFS

(TKI vs Chemo), p

PFS HR

(95%CI)

ORR% (TKI vs Chemo)

≥G3 TKI

tox (%)

OS HR

(95%CI)

LUX-7

Gefitinib

Afatinib

319 11.0 vs 10.9; p=0.017 0.73

(0.58-0.92)

70 vs 56

31 vs 18 0.86 (0.66-

1.12)

ARCHER

1050

Gefitinib

Dacomitinib

452 14.7 vs 9.2; p<0.0001 0.59

(0.47-0.74)

75 vs 72

42 vs 9.3 0.76 (0.58-

0.99)

FLAURA

Gefitinib/

Erlotinib

Osimertinib

556 18.9 vs 10.2; p<0.001 0.46

(0.37-0.57)

80 vs 76

18 vs 28 0.63 (0.45-

0.88)*

83% vs 71%

at 18 mo

*immature data

Park K et al Lancet Oncol 2016; Paz-Arez L et al Ann Oncol 2017; Wu YL et al Lancet Oncol 2017; Mok T et al J Clin Oncol 2018; Soria JC et al NEJM 2017;

NR, not reported